Skip to main content

Table 2 Bayesian Analysis of ADCOMS at 12 months—full analysis set

From: A randomized, double-blind, phase 2b proof-of-concept clinical trial in early Alzheimer’s disease with lecanemab, an anti-Aβ protofibril antibody

  Change from baseline Posterior quantities*
Treatment group Total N Mean SD Pr (Max) Pr (ED90) Pr Superiority Pr (CSD)
ADCOMS—overall
 Placebo control 229 0.113 0.012
 2.5 mg/kg biweekly 51 0.134 0.024 0.009 0.009 0.216 0.028
 5 mg/kg monthly 48 0.119 0.021 0.022 0.031 0.416 0.070
 5 mg/kg biweekly 87 0.116 0.016 0.010 0.010 0.446 0.053
 10 mg/kg monthly 242 0.084 0.011 0.318 0.386 0.961 0.479
 10 mg/kg biweekly 143 0.077 0.014 0.642 0.563 0.976 0.638
  1. Only subjects with non-missing data at both baseline and the relevant post-baseline visit are included in the change from baseline summary statistics
  2. ADCOMS, Alzheimer’s Disease Composite Score; CSD, clinically significant difference; 25% better than placebo, ED90, dose regimen with at least 90% of the dmax treatment effect; Max, maximum treatment effect; Pr, probability; Pr (Max), probability of being maximal effective dose; Pr (ED90), probability of being the ED90 dose; Pr (Superiority), probability to be superior to placebo by any magnitude; Pr (CSD), probability to be better than placebo by at least 25%
  3. *Probabilities can be interpreted as a percentage (e.g., 0.10 is 10%)